Cancer Drug Design and Discovery

Section I. Basic Principles 1. Modern cancer drug discovery: Integrating targets, technologies and treatments2. Preclinical pharmacology and in vivo models 3. Clinical trial designs for more rapid proof-of-principle and approval Section II. Methodology 4. Structural biology and anticancer drug design5. Natural product chemistry and cancer drug discovery 6. Pharmacokinetics & ADME optimization in drug discoverySection III. Drugs in the clinic and laboratory7. Temozolomide: from cytotoxic to molecularly-targeted agent 8. Camptothecins for drug design, cancer cell death and gene targeting9. Targeting thymidylate synthase by antifolate drugs for the treatment of cancerSection IV. New Agents 10. Targeting inactive kinases: structure as a foundation for cancer drug discovery11. Cell cycle inhibitors in cancer: current status and future directions 12. Inhibition of DNA repair as a therapeutic target 13. Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways14. Heat shock protein-90-directed therapeutics and target validation15. Inhibitors of tumour angiogenesis16. The biology and oncology of RAF-ERK signalling P53 as a therapeutic targetSection V. The reality of cancer drugs in the clinic17. Cancer drug resistance 18. Failure Modes in Anticancer Drug Discovery and Development